Multifunctional proteins are challenging as it can be difficult to confirm pathomechanisms associated with disease-causing genetic variants. The human 17β-hydroxysteroid dehydrogenase 10 (HSD10) is a moonlighting enzyme with at least two structurally and catalytically unrelated functions. HSD10 disease was originally described as a disorder of isoleucine metabolism, but the clinical manifestations were subsequently shown to be linked to impaired mtDNA transcript processing due to deficient function of HSD10 in the mtRNase P complex. A surprisingly large number of other, mostly enzymatic and potentially clinically relevant functions have been attributed to HSD10. Recently, HSD10 was reported to exhibit phospholipase C-like activity towards cardiolipins (CL), important mitochondrial phospholipids. To assess the physiological role of the proposed CL-cleaving function, we studied CL architectures in living cells and patient fibroblasts in different genetic backgrounds and lipid environments using our well-established LC-MS/MS cardiolipidomic pipeline. These experiments revealed no measurable effect on CLs, indicating that HSD10 does not have a physiologically relevant function towards CL metabolism. Evolutionary constraints could explain the broad range of reported substrates for HSD10 in vitro. The combination of an essential structural with a non-essential enzymatic function in the same protein could direct the evolutionary trajectory towards improvement of the former, thereby increasing the flexibility of the binding pocket, which is consistent with the results presented here.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587951PMC
http://dx.doi.org/10.1007/s00018-022-04579-6DOI Listing

Publication Analysis

Top Keywords

hsd10
8
function
5
ost promiscuity?
4
promiscuity? evolutionary
4
evolutionary biochemical
4
biochemical evaluation
4
evaluation hsd10
4
hsd10 function
4
function cardiolipin
4
cardiolipin metabolism
4

Similar Publications

Alzheimer's disease (AD) is estimated to affect over 55 million people across the world. Small molecule treatment options are limited to symptom management with no impact on disease progression. The need for new protein targets and small molecule hit compounds is unmet and urgent.

View Article and Find Full Text PDF
Article Synopsis
  • LD14b is a promising compound that can counteract the negative effects of amyloid-β (Aβ) on mitochondrial function and hormone synthesis.
  • The study evaluated LD14b's stability, permeability, protein binding, and distribution in Balb/cJ mice, utilizing a reliable LC-MS/MS method for quantification.
  • Results indicated that LD14b is metabolically stable in the human liver, has moderate absorption predicted in mice, and is effectively distributed to various tissues, including the brain.
View Article and Find Full Text PDF

Introduction: Hydroxysteroid 17-beta dehydrogenase type 10 (HSD10) protein is a mitochondrial enzyme. Multisystemic involvement occurs in HSD10 deficiency as in other mitochondrial diseases. HSD10 deficiency (disease) is rare.

View Article and Find Full Text PDF

17β-HSD10 is a mitochondrial enzyme that catalyzes the steroidal oxidation of a hydroxy group to a keto group and, thus, is involved in maintaining steroid homeostasis. The druggability of 17β-HSD10 is related to potential treatment for neurodegenerative diseases, for example, Alzheimer's disease or cancer. Herein, steroidal derivatives with an acidic hemiester substituent at position C-3 on the skeleton were designed, synthesized, and evaluated by using pure recombinant 17β-HSD10 converting 17β-estradiol to estrone.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!